Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Duvelisib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Venetoclax chronic lymphocytic leukemia not applicable detail...
Unknown unknown AMG 319 chronic lymphocytic leukemia not applicable detail...
Unknown unknown Acalabrutinib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Ibrutinib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Copanlisib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Idelalisib + Rituximab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Entospletinib + Idelalisib chronic lymphocytic leukemia not applicable detail...
TP53 mutant Duvelisib chronic lymphocytic leukemia predicted - sensitive detail...
Unknown unknown Ublituximab + Umbralisib chronic lymphocytic leukemia not applicable detail...
Unknown unknown PRT062607 chronic lymphocytic leukemia not applicable detail...
Unknown unknown PRT318 chronic lymphocytic leukemia not applicable detail...
Unknown unknown Entospletinib chronic lymphocytic leukemia not applicable detail...
TP53 inact mut AZD6482 chronic lymphocytic leukemia predicted - sensitive detail...
ATM loss AZD6482 chronic lymphocytic leukemia sensitive detail...
TP53 inact mut AZD6738 + Ibrutinib chronic lymphocytic leukemia sensitive detail...
ATM loss AZD6738 + Ibrutinib chronic lymphocytic leukemia sensitive detail...
Unknown unknown Lenalidomide + Ofatumumab chronic lymphocytic leukemia not applicable detail...
ATM inact mut Olaparib chronic lymphocytic leukemia sensitive detail...
Unknown unknown Chlorambucil + Ofatumumab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Ofatumumab chronic lymphocytic leukemia not applicable detail...
Unknown unknown ONO-4059 chronic lymphocytic leukemia not applicable detail...
Unknown unknown Obinutuzumab + Chlorambucil chronic lymphocytic leukemia not applicable detail...
Unknown unknown ARQ 531 chronic lymphocytic leukemia not applicable detail...
Unknown unknown Idelalisib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Cyclophosphamide + Fludarabine + Ofatumumab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Samalizumab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Bendamustine + Idelalisib + Rituximab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Safingol chronic lymphocytic leukemia not applicable detail...
Unknown unknown Cerdulatinib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Cerdulatinib + Venetoclax chronic lymphocytic leukemia not applicable detail...
Unknown unknown Bortezomib + Tinostamustine chronic lymphocytic leukemia not applicable detail...
Unknown unknown Carfilzomib + EDO-S101 chronic lymphocytic leukemia not applicable detail...
Unknown unknown Bendamustine + MK2206 + Rituximab chronic lymphocytic leukemia not applicable detail...
Unknown unknown Umbralisib chronic lymphocytic leukemia not applicable detail...
Unknown unknown Ibrutinib + Venetoclax chronic lymphocytic leukemia not applicable detail...
TP53 mutant Ibrutinib + Venetoclax chronic lymphocytic leukemia predicted - sensitive detail...
Unknown unknown Cyclophosphamide + Fludarabine + Rituximab chronic lymphocytic leukemia not applicable detail...
Unknown unknown GS-9820 chronic lymphocytic leukemia not applicable detail...
Unknown unknown LAM-002A chronic lymphocytic leukemia not applicable detail...
Unknown unknown STRO-001 chronic lymphocytic leukemia sensitive detail...
Unknown unknown Bendamustine + Obinutuzumab + Venetoclax chronic lymphocytic leukemia not applicable detail...
Unknown unknown Milatuzumab chronic lymphocytic leukemia sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed
NCT00577278 Phase II Ibritumomab Sirolimus + Tacrolimus + Methotrexate Rituximab Fludarabine + Melphalan Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00829647 Phase Ib/II Dasatinib + lenalidomide A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia Withdrawn
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa Busulfan + Clofarabine + Thymoglobulin Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Active, not recruiting
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT01125176 Phase II Lenalidomide + Rituximab + Thalidomide Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL Active, not recruiting
NCT01173679 Phase II Dasatinib + Rituximab + Fludarabine Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Terminated
NCT01193842 Phase Ib/II Vorinostat R-EPOCH Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
NCT01296932 Phase I BI 836826 BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting
NCT01441882 Phase II Dasatinib A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity Completed
NCT01459211 Phase II Dexamethasone Lenalidomide Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) Completed
NCT01532700 Phase II Ofatumumab + GSK2110183 An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) Completed
NCT01556776 Phase III Lenalidomide A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Active, not recruiting
NCT01604031 Phase Ib/II Lenalidomide Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Terminated
NCT01638533 Phase I romidepsin Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Recruiting
NCT01644253 Phase I Idelalisib + Otlertuzumab + Rituximab Otlertuzumab + Rituximab Obinutuzumab + Otlertuzumab Ibrutinib + Otlertuzumab Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia Active, not recruiting
NCT01660451 Phase II Copanlisib Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas Active, not recruiting
NCT01671904 Phase I Bendamustine + Obinutuzumab + Venetoclax Bendamustine + GDC-0199 + Rituximab A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia Active, not recruiting
NCT01685892 Phase I GDC-0199 + Obinutuzumab A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia Active, not recruiting
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated
NCT01750567 Phase II Metformin A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL Recruiting
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01822509 Phase I Nivolumab + Ipilimumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Active, not recruiting
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated
NCT01849276 Phase I Metformin + Cytarabine Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Terminated
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Active, not recruiting
NCT01889186 Phase II Venetoclax A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion Active, not recruiting
NCT01905813 Phase I Itacitinib + INCB040093 INCB040093 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT01980875 Phase III Idelalisib + Obinutuzumab Obinutuzumab + Chlorambucil Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Terminated
NCT01980888 Phase III Bendamustine + Idelalisib + Rituximab Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Terminated
NCT02000934 Phase I TAK-659 A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting
NCT02004522 Phase III Duvelisib Ofatumumab A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) Active, not recruiting
NCT02005289 Phase II Lenalidomide + MOR208 Ibrutinib + MOR208 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Active, not recruiting
NCT02005471 Phase III Venetoclax Bendamustine Rituximab A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting
NCT02015208 Phase Ib/II Ruxolitinib Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia Completed
NCT02018861 Phase I Itacitinib INCB039110 + INCB050465 Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide INCB050465 A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02044822 Phase II Idelalisib + Rituximab Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Terminated
NCT02049515 Phase III Ofatumumab Duvelisib A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 Enrolling by invitation
NCT02061761 Phase Ib/II Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Recruiting
NCT02100423 Phase II Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
NCT02100852 Phase I Chlorambucil + Obinutuzumab + Umbralisib TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02131584 Phase II Ruxolitinib Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02135133 Phase II Idelalisib + Ofatumumab A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Active, not recruiting
NCT02141282 Phase II Venetoclax A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy Active, not recruiting
NCT02158091 Phase Ib/II Cyclophosphamide + Fludarabine + Rituximab Duvelisib A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL Active, not recruiting
NCT02160015 Phase I Rituximab + Lenalidomide + Ibrutinib Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated
NCT02200848 Phase I Rituximab + Lenalidomide + Ibrutinib Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL Terminated
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
NCT02222688 Phase I Cirmtuzumab UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Active, not recruiting
NCT02242942 Phase III Obinutuzumab + Chlorambucil GDC-0199 + Obinutuzumab A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Active, not recruiting
NCT02249429 Phase Ib/II PQR309 Open-Label, Non Randomized Phase 2 Study With Safety Run-In Completed
NCT02251548 Phase II Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Active, not recruiting
NCT02268851 Phase I Ibrutinib + Umbralisib A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Active, not recruiting
NCT02285244 Phase II AEB071 Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation Withdrawn
NCT02292225 Phase I Duvelisib + Obinutuzumab IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi Terminated
NCT02296918 Phase I Acalabrutinib + Obinutuzumab ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL Active, not recruiting
NCT02301156 Phase III Ublituximab Ibrutinib Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Recruiting
NCT02315768 Phase Ib/II Ibrutinib + Obinutuzumab Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Active, not recruiting
NCT02319369 Phase I DS-3032b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Recruiting
NCT02332980 Phase II Pembrolizumab A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma Recruiting
NCT02340780 Phase II Buparlisib Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia Active, not recruiting
NCT02361346 Phase I MT-3724 PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia (MT-3724NHL001) Recruiting
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Active, not recruiting
NCT02420912 Phase II Ibrutinib + Nivolumab Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT02427451 Phase Ib/II GDC-0199 + Ibrutinib + Obinutuzumab Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02475681 Phase III Acalabrutinib Chlorambucil Obinutuzumab Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL Active, not recruiting
NCT02477696 Phase III Acalabrutinib Ibrutinib Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia Active, not recruiting
NCT02535286 Phase Ib/II Pembrolizumab + Ublituximab + Umbralisib Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL Recruiting
NCT02537613 Phase I Ibrutinib + Obinutuzumab A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Recruiting
NCT02538614 Phase Ib/II BI 836826 + Idelalisib Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia Terminated
NCT02557516 Phase Ib/II IPH2201 Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia Active, not recruiting
NCT02580552 Phase I MRG-106 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Recruiting
NCT02611908 Phase I Ibrutinib + Obinutuzumab Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. Withdrawn
NCT02612311 Phase III Ublituximab Obinutuzumab + Chlorambucil Umbralisib Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Active, not recruiting
NCT02639910 Phase II MOR208 + Venetoclax Idelalisib + MOR208 Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Active, not recruiting
NCT02649387 Phase II Ibrutinib Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT) Recruiting
NCT02656303 Phase II Ublituximab + Umbralisib An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 Recruiting
NCT02684617 Phase I Dinaciclib + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) (KEYNOTE-155) Recruiting
NCT02717611 Phase II Acalabrutinib A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy Active, not recruiting
NCT02733042 Phase Ib/II Rituximab lenalidomide + MEDI4736 + Rituximab Bendamustine + MEDI4736 + Rituximab Ibrutinib + MEDI4736 Durvalumab A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) Active, not recruiting
NCT02742090 Phase II Umbralisib Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy Active, not recruiting
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn
NCT02756611 Phase III Venetoclax A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors Active, not recruiting
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting
NCT02801578 Phase I Ibrutinib A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) Completed
NCT02846623 Phase II Atezolizumab + Obinutuzumab Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT02860676 Phase I Cirmtuzumab Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 Completed
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Recruiting
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Recruiting
NCT02912754 Phase Ib/II Ibrutinib Ibrutinib + Ruxolitinib Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients Not yet recruiting
NCT02914327 Phase I Ibrutinib + SNX-5422 Safety and Activity of SNX-5422 Plus Ibrutinib in CLL Withdrawn
NCT02948283 Phase 0 Metformin + Ritonavir Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Active, not recruiting
NCT02970318 Phase III Bendamustine + Idelalisib + Rituximab Acalabrutinib A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Active, not recruiting
NCT02973399 Phase I Ibrutinib + SNX-5422 Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL Terminated
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting
NCT03037645 Phase Ib/II SNS-062 Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Recruiting
NCT03041636 Phase II Ruxolitinib Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT03045328 Phase Ib/II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Recruiting
NCT03056339 Phase Ib/II Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Recruiting
NCT03069469 Phase I DCC-3014 Study of DCC-3014 in Patients With Advanced Malignancies Recruiting
NCT03128879 Phase II Allopurinol + Ibrutinib + Venetoclax Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Recruiting
NCT03153202 Phase Ib/II Pembrolizumab + Ibrutinib Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Recruiting
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03207256 Phase II Ublituximab + Umbralisib Umbralisib Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials Enrolling by invitation
NCT03207555 Phase II Ibrutinib Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) Recruiting
NCT03219450 Phase I NeoVax Cyclophosphamide + NeoVax A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naive, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia. Not yet recruiting
NCT03283137 Phase I Pembrolizumab + Umbralisib Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Recruiting
NCT03331198 Phase Ib/II JCAR017 Ibrutinib + JCAR017 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004) Recruiting
NCT03370185 Phase II Duvelisib Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Suspended
NCT03379051 Phase Ib/II Ublituximab + Umbralisib + Venetoclax Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Recruiting
NCT03400176 Phase I Ibrutinib + VAY736 VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib Recruiting
NCT03406156 Phase III Bendamustine + Obinutuzumab GDC-0199 + Obinutuzumab Bendamustine A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Recruiting
NCT03422393 Phase I Ibrutinib + Venetoclax Venetoclax Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib Recruiting
NCT03447808 Phase I Daratumumab + Ibrutinib Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Recruiting
NCT03462719 Phase III Obinutuzumab + Chlorambucil Ibrutinib + Venetoclax A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Recruiting
NCT03467867 Phase II Hyaluroinidase + Rituximab + Venetoclax GDC-0199 + Rituximab A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL Recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03513562 Phase II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations Not yet recruiting
NCT03514017 Phase II Pembrolizumab + Ibrutinib Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia Not yet recruiting
NCT03534323 Phase Ib/II GDC-0199 + Duvelisib Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL Recruiting
NCT03580928 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) Recruiting
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Not yet recruiting
NCT03609593 Phase II Rituximab Bendamustine + Rituximab Venetoclax Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Not yet recruiting
NCT03624036 Phase Ib/II Cyclophosphamide + Fludarabine KTE-C19 Safety and Efficacy of KTE-C19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia (ZUMA-8) Recruiting
NCT03639324 Phase I Idelalisib + Rituximab + Venetoclax Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL) Not yet recruiting
NCT03701282 Phase III Ibrutinib + Obinutuzumab GDC-0199 + Ibrutinib + Obinutuzumab Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia Recruiting
NCT03737981 Phase III GDC-0199 + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia Recruiting
NCT03739554 Phase I CYC065 + Venetoclax CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL Recruiting
NCT03759184 Phase I Obinutuzumab + rhIL-15 Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Recruiting
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting
NCT03824483 Phase II BGB-3111 + Obinutuzumab + Venetoclax Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Recruiting
NCT03836261 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL Not yet recruiting